AbbVie has reported positive results from Part B of the Phase 2 APEX study of zumilokibart in adults with moderate to severe atopic dermatitis, presenting the findings as a late-breaking presentation at the European Academy of Dermatology and Venereology (EADV) 2026 congress.

The company described the outcome as positive across the study's Part B evaluation, marking the second readout from the APEX program and the most advanced clinical signal to date for a molecule AbbVie has positioned within its immunology pipeline as a next-generation approach to type 2 inflammation.

Zumilokibart is an investigational biologic designed to inhibit interleukin-13 (IL-13) signaling, a cytokine central to the pathophysiology of atopic dermatitis. IL-13 blockade is a validated mechanism in the disease: lebrikizumab, another IL-13 inhibitor, has already established registrational efficacy in moderate to severe atopic dermatitis on EASI and IGA endpoints. Zumilokibart, however, targets the IL-13 pathway through a differentiated binding profile, and the APEX program has been the vehicle for testing whether that differentiation translates into clinically meaningful outcomes.

Part B of APEX followed an earlier Part A evaluation, and together the two segments form AbbVie's Phase 2 proof-of-concept package in atopic dermatitis. The decision to place the Part B results in a late-breaking slot at EADV 2026 — a forum typically reserved for practice-changing or first-disclosure trial data — signals the company's intent to put the dataset in front of the European dermatology community directly rather than through a press release alone.

The stakes for AbbVie are considerable. The atopic dermatitis market has become one of the most competitive spaces in dermatology, with dupilumab holding an established frontline position among biologics, lebrikizumab and tralokinumab competing in the IL-13 class, and a growing roster of oral small molecules, including JAK inhibitors, reshaping treatment sequencing at earlier lines of therapy. For a pipeline candidate to justify advancement into Phase 3, a Phase 2 program must show not only that the mechanism works — that much is established — but that the molecule offers something the existing agents do not, whether in magnitude of EASI response, durability, safety, dosing convenience, or performance in specific patient subpopulations.

AbbVie has not yet disclosed the detailed endpoint-level results from APEX Part B in the materials accompanying the congress announcement. The full dataset — presumably including EASI-75 and EASI-90 response rates, IGA responses, pruritus measures such as the Peak Pruritus NRS, and safety and tolerability findings across treatment arms — is expected to be available in the congress proceedings and peer-reviewed publication.

For practicing dermatologists, the immediate clinical relevance is limited while the detailed numbers remain pending, but the development is worth tracking for two reasons. First, it confirms that the IL-13 target continues to attract investment despite an increasingly crowded field, suggesting manufacturers see remaining unmet need in atopic dermatitis care — particularly in patients with inadequate response or tolerability issues on current agents. Second, a positive Phase 2 readout in a program of this design typically precedes a Phase 3 decision, meaning pivotal trials could begin enrolling within the year if the data hold up under full scrutiny.

The next milestones to watch are the peer-reviewed publication of the APEX Part B results with full efficacy and safety tables, any regulatory engagement on the design of a Phase 3 program, and AbbVie's commentary on how zumilokibart would be positioned against its own existing immunology portfolio if it reaches the market.